Therefore, we hypothesized that targeting of IL-6 signaling could reverse the resistant phenotype in tumor cells, thereby enhancing the anti-tumor effects of cisplatin and radiation treatment in HNSCC. This evidence concerns the gene IL6 and neoplasm.